{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:20Z","timestamp":1791231440896,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.cancergencyto.2007.09.014","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T21:31:23Z","timestamp":1197322283000},"page":"60-64","source":"Crossref","is-referenced-by-count":12,"title":["Amplification of BCR\u2013ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia"],"prefix":"10.1016","volume":"180","author":[{"given":"Chin-Lee","family":"Phan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puteri J.N.B.","family":"Megat Baharuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Peng","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubaidah","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Yegappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameela","family":"Sathar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen-Mui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visalachy","family":"Purushothaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian-Meng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2007.09.014_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0165-4608(02)00854-3","article-title":"Amplification of the BCR\/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemia","volume":"143","author":"Gargallo","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2005.1.188","article-title":"Pathobiology of lymphoid and myeloid blast crisis and management issues","author":"Ilaria","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib3","first-page":"1333","article-title":"The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic leukemia with secondary chromosomal aberrations","volume":"9","author":"Mohamed","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib4","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V86.1.1.bloodjournal8611","article-title":"AML1 and the 8;21 and 3;21 translocation in acute and chronic myeloid leukemia","volume":"86","author":"Nucifora","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/j.1460-2075.1994.tb06288.x","article-title":"Generation of the AML1\u2013EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia","volume":"13","author":"Mitani","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib7","first-page":"2728","article-title":"Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis","volume":"81","author":"Nucifora","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib8","article-title":"ISCN 2005: an international system for human cytogenetic nomenclature (2005)","year":"2005"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib9","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/09674845.2004.11732653","article-title":"Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia","volume":"61","author":"Knight","year":"2004","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib11","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib13","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib14","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/j.1460-2075.1987.tb02420.x","article-title":"Structure of an inverted duplication formed as a first step in a gene amplification event: implications for a model of gene amplification","volume":"6","author":"Passananti","year":"1987","journal-title":"EMBO J"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib16","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/MCB.15.5.2383","article-title":"Dual functions of the AML1\/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias","volume":"15","author":"Tanaka","year":"1995","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib17","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1038\/sj.onc.1205095","article-title":"Cooperation of BCR\u2013ABL and AML1\/MDS1\/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia","volume":"20","author":"Cuenco","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.onc.1207143","article-title":"Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1\/MDS1\/EVI1 with BCR\/ABL in the induction of acute myelogenous leukemia in mice","volume":"23","author":"Cuenco","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib19","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.leu.2403931","article-title":"Coexistence of AML1\/RUNX1 and BCR\u2013ABL point mutations in an imatinib-resistant form of CML","volume":"19","author":"Corm","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0165-4608(02)00566-6","article-title":"AML1 amplification in a case of childhood acute lymphoblastic leukemia","volume":"137","author":"Morel","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0165-4608(02)00639-8","article-title":"AML1 amplification in a child with acute lymphoblastic leukemia","volume":"140","author":"Alvarez","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib22","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1038\/sj.leu.2403140","article-title":"Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome","volume":"17","author":"Robinson","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib23","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2004-02-0754","article-title":"Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation","volume":"104","author":"Christiansen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib24","first-page":"225","article-title":"Overcoming resistance to imatinib by combining targeted agents","volume":"2","author":"Druker","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2007.09.014_bib26","first-page":"1248","article-title":"Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance","volume":"9","author":"Marcucci","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460807005936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460807005936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T09:56:10Z","timestamp":1588154170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460807005936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0165460807005936"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2007.09.014","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}